PATENT CLAIM ANALYSIS

Application Number: 16152463
Application Type: Utility
Filing Date: 2018-10
Publication Date: 2019-02
Patent Classification: ["514", "183000"]

Abstract:
Concentrated methotrexate solutions are described which are suitable for the use of an active substance in the production of a parenterally administered medicament for the treatment of inflammatory autoimmune diseases. The methotrexate is added to a pharmaceutically acceptable solvent at a concentration of more than 25 mg/ml.

Claim (Index 8):
The method according to  claim 1 , wherein the inflammatory autoimmune disease is selected from rheumatoid arthritis, juvenile arthritides, vasculitides, collagenoses, Crohn's disease, colitis ulcerosa, bronchial asthma, Alzheimer's disease, multiple sclerosis, Bechterew's disease, joint arthroses, and psoriasis.

Metadata:
- Claim Count in Document: 83.0
- Percentile: 97.0
- Lexical Diversity: 1.28947
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['12374528', '14158289', '13257555', '13607659', '15193815']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.759636410535682
- 35 USC 102 Novelty (BERT): 0.5392227393903551
- Combined Prediction Score: 0.7375950434211492
- Mean Citation Score: 209.392768
- Max Citation Score: 362.4949
- Similarity Product: 310.4020912800789

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test